The high baseline levels of NT-proBNP tended to normalize at one-year follow-up, and a 12-month 10% increment of NT-proBNP is associated with a 35% higher risk for an adverse CVE in patients with CHD. This evidence concerns the gene NPPB and coronary artery disorder.